[go: up one dir, main page]

AR058266A1 - Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica - Google Patents

Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica

Info

Publication number
AR058266A1
AR058266A1 ARP060105332A ARP060105332A AR058266A1 AR 058266 A1 AR058266 A1 AR 058266A1 AR P060105332 A ARP060105332 A AR P060105332A AR P060105332 A ARP060105332 A AR P060105332A AR 058266 A1 AR058266 A1 AR 058266A1
Authority
AR
Argentina
Prior art keywords
spirociclic
derivatives
therapeutic application
pde7
pde7 inhibiting
Prior art date
Application number
ARP060105332A
Other languages
English (en)
Inventor
David J Rawson
Nigel A Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR058266A1 publication Critical patent/AR058266A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente proporciona compuestos de formula (1) en la que m es 0, 1 o 2; X es O, S o N-CN; R es F, Cl o CN; A es un grupo cicloalquileno C3-6 opcionalmente sustituido con un grupo alquilo C1-4; y B es un enlace sencillo o un grupo alquileno C1-2; o una de sus sales, solvatos, polimorfismos o profármacos farmacéuticamente aceptable. Los compuestos son inhibidores de PDE7 y tienen una diversidad de aplicaciones terapéuticas, particularmente en el tratamiento del dolor, especialmente dolor neuropático.
ARP060105332A 2005-12-02 2006-12-01 Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica AR058266A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10

Publications (1)

Publication Number Publication Date
AR058266A1 true AR058266A1 (es) 2008-01-30

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105332A AR058266A1 (es) 2005-12-02 2006-12-01 Derivados espirociclicos inhibidores de pde7 y su aplicacion terapeutica

Country Status (22)

Country Link
US (1) US7507742B2 (es)
EP (1) EP1957467A2 (es)
JP (1) JP2009517453A (es)
KR (1) KR101009554B1 (es)
AP (1) AP2008004470A0 (es)
AR (1) AR058266A1 (es)
AU (1) AU2006321349A1 (es)
BR (1) BRPI0619126A2 (es)
CA (1) CA2631535C (es)
CR (1) CR10039A (es)
EA (1) EA200801145A1 (es)
EC (1) ECSP088484A (es)
GT (1) GT200600494A (es)
MA (1) MA30014B1 (es)
ME (1) MEP0408A (es)
NL (1) NL2000336C2 (es)
NO (1) NO20082077L (es)
PE (1) PE20071087A1 (es)
RS (1) RS20080233A (es)
TW (1) TW200732307A (es)
UY (1) UY29979A1 (es)
WO (1) WO2007063391A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
JP4173909B1 (ja) * 2005-04-28 2008-10-29 ファイザー・リミテッド アミノ酸誘導体
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
NZ580413A (en) * 2007-03-27 2012-11-30 Omeros Corp The use of pde7 inhibitors for the treatment of movement disorders
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
EP2116618A1 (en) * 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
NZ610925A (en) 2010-11-08 2015-10-30 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP3652180B1 (en) * 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
IL318817A (en) 2022-08-18 2025-04-01 Mitodicure Gmbh Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138815A1 (en) 2000-04-28 2003-07-24 Franz-Werner Kluxen Splice variant of camp phosphodiesterase type7(pde7a3)
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain

Also Published As

Publication number Publication date
US20070129388A1 (en) 2007-06-07
PE20071087A1 (es) 2007-12-29
NO20082077L (no) 2008-06-04
UY29979A1 (es) 2007-06-29
NL2000336A1 (nl) 2007-06-05
KR20080059338A (ko) 2008-06-26
CA2631535A1 (en) 2007-06-07
AP2008004470A0 (en) 2008-06-30
GT200600494A (es) 2007-07-06
US7507742B2 (en) 2009-03-24
ECSP088484A (es) 2008-06-30
TW200732307A (en) 2007-09-01
EP1957467A2 (en) 2008-08-20
CA2631535C (en) 2010-07-27
AU2006321349A1 (en) 2007-06-07
JP2009517453A (ja) 2009-04-30
EA200801145A1 (ru) 2008-10-30
CR10039A (es) 2008-07-10
RS20080233A (sr) 2009-07-15
WO2007063391A2 (en) 2007-06-07
BRPI0619126A2 (pt) 2011-09-13
MA30014B1 (fr) 2008-12-01
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (en) 2007-09-13
MEP0408A (xx) 2010-02-10
NL2000336C2 (nl) 2007-08-07

Similar Documents

Publication Publication Date Title
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
ECSP099376A (es) Inhibidores de la actividad de la akt
ECSP034896A (es) Derivados aromaticos de acidos dicarboxilicos
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
NI200700320A (es) Inhibidores de la actividad akt
NO20052787D0 (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
DK1709044T3 (da) Oxazolidinon-quinolon-hybridantibiotika
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
CR20220308A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
NO20091495L (no) Pyrazolopyrimidinderivat
SE0003476D0 (sv) Compounds
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse
DOP2006000279A (es) Derivados espirocíclicos
EA200600549A1 (ru) Ингибиторы каспаз в качестве материала для покрытия медицинских продуктов для ингибирования рестеноза
MX2024005267A (es) Moduladores de akt3.
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure